Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to compare the efficacy of 2-days versus 5-days octreotide infusion after endoscopic therapy in preventing early esophageal varices rebleed in patients with cirrhosis.


Clinical Trial Description

Variceal hemorrhage, causative of 70% of all upper gastrointestinal (GIT) bleeding events in patients with portal hypertension, remains one of the most severe and immediate life-threatening complications in patients with cirrhosis and constitutes the second most frequent decompensating event after ascites . Gastro-esophageal varices are identified in about 30% of patients with compensated cirrhosis and 60% of patients with de-compensated cirrhosis . Esophageal variceal bleeding (EVB) occurs in 10-20% of cirrhotic patients per year and each bleeding episode can be associated with in-hospital mortality . Mortality during the first episode is estimated to 15-20% but is higher in severe patients (Child Pugh C), at around 30%, whereas it is very low in patients with compensated cirrhosis (Child Pugh A) .The main predictors of bleeding in clinical practice are: large versus small varices, red wale marks, Child Pugh C versus Child Pugh A-B . Treatment of variceal bleeding should be started as soon as bleeding is clinically confirmed, regardless the lack of confirmation by upper endoscopy . Initial therapy should be directed at restoring blood volume. Vasoactive drug therapy and antibiotic prophylaxis should be initiated as soon as AVB is suspected. Goals of therapy in AVB include the control of bleeding, as well as the prevention of early recurrence and the prevention of six-week mortality . Starting vasoactive drugs before endoscopy decreases the incidence of active bleeding during endoscopy and facilitates endoscopic therapy, improving the control of bleeding, and potentially survival. Terlipressin, somatostatin or octreotide are accepted drugs with proven efficacy . Once AVB is confirmed, vasoactive drug therapy should be administered for five days to avoid early rebleeding. Shorter administration of vasoactive drugs (48-72 h) can be considered in less severe episodes although more data are required .The optimal duration of pharmacological therapy has not been well established. In randomized-controlled trials, the duration of vasoactive drugs has varied between 8 h and 6 days . There was a major agreement that an appropriate length of therapy would be anywhere between 2 and 5 days depending on control of hemorrhage and the presence or absence of predictors of rebleeding . The combination of endoscopic therapy and vasoactive drugs is more effective than the isolated use of either of these options alone, because it combines the local haemostatic effect on the varices induced by endoscopic treatment and the portal hypotensive effect achieved with drugs. This combination is currently considered the standard of care in AVB . ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05199038
Study type Interventional
Source Tanta University
Contact Mennat -Allah M. El Sawaf, master
Phone 00201225548976
Email [email protected]
Status Not yet recruiting
Phase Phase 4
Start date June 2022
Completion date November 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03624517 - Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices Phase 4
Recruiting NCT03989973 - Two-dimensional Shear-Wave Elastography Evaluate Esophageal Varices Bleeding Risk of Liver Cirrhosis
Completed NCT01851252 - MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy Phase 1
Completed NCT01360515 - A Study of Disposable Transnasal Esophagoscope N/A
Recruiting NCT04602663 - Optimal Time for Follow up After Variceal Band Ligation N/A
Recruiting NCT04499898 - Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding Phase 2/Phase 3
Completed NCT00331188 - Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Phase 3
Enrolling by invitation NCT02767206 - Evaluation of Gastroesophageal Varices by Transnasal Endoscopy. N/A
Recruiting NCT02740166 - Preventing Recurrent Bleeding After Eradication of Esophageal Varices Phase 4
Completed NCT01893541 - PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES? Phase 4
Terminated NCT00485290 - Effect of Meal on Portal and Esophagus Variceal Pressure N/A
Completed NCT01079416 - Study of Capsule Endoscopy to Determine the Accuracy for Detection of Esophageal Varices N/A
Completed NCT01188733 - Efficacy of Long-acting Octreotide (Sandostatin LAR) in Reducing Portal Pressure in Patients With Cirrhosis Phase 1/Phase 2
Not yet recruiting NCT04254822 - HVPG-Guided Therapy vs Carvedilol Plus Endotherapy for the Prevention of Esophageal Variceal Rebleeding in Cirrhotic Patients N/A
Recruiting NCT03212872 - Blood Ammonia as Predictor for Esophageal Varices and Risk of Bleeding N/A
Recruiting NCT03748563 - Accuracy of Magnetically Maneuvered Capsule Endoscopy for Detection of GEV in Patients With Cirrhosis N/A
Completed NCT01059396 - Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal Phase 4
Completed NCT01242280 - Self-expandable Esophageal Stent Versus Balloon Tamponade in Refractory Esophageal Variceal Bleeding. Phase 3
Completed NCT00587197 - A Prospective Evaluation of Computerized Tomographic(CT) Scanning as a Screening Modality for Esophageal Varices N/A
Completed NCT04976543 - Safety of Anticoagulant Therapy After Variceal Band Ligation Phase 4